Evidence map›Paper›PMID 37162525›Full record

ArticleAnalytical and bioanalytical chemistry2023

Demonstrating analytical similarity of a biosimilar HLX04 to bevacizumab with a panel of state-of-the-art methods and tiering of quality attributes.

Lei Zhang, Lu Yu, Yanpeng Xu, Peilan Qin, Pengcheng Shen, Kemeng Liu, Mengdan Fei, Hongya Wang, Yanjing Cao, Lihong Lu and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Analytical and bioanalytical chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Lei ZhangDepartment of Analytical Science and Development, Shanghai Henlius Biologics Co., Ltd, 5155 Guangfulin Road, Shanghai, 201600, China.
Lu YuDepartment of Analytical Science and Development, Shanghai Henlius Biologics Co., Ltd, 5155 Guangfulin Road, Shanghai, 201600, China.
Yanpeng XuDepartment of Analytical Science and Development, Shanghai Henlius Biologics Co., Ltd, 5155 Guangfulin Road, Shanghai, 201600, China.
Peilan QinDepartment of Analytical Science and Development, Shanghai Henlius Biologics Co., Ltd, 5155 Guangfulin Road, Shanghai, 201600, China.
Pengcheng ShenDepartment of Analytical Science and Development, Shanghai Henlius Biologics Co., Ltd, 5155 Guangfulin Road, Shanghai, 201600, China.
Kemeng LiuDepartment of Analytical Science and Development, Shanghai Henlius Biologics Co., Ltd, 5155 Guangfulin Road, Shanghai, 201600, China.
Mengdan FeiDepartment of Analytical Science and Development, Shanghai Henlius Biologics Co., Ltd, 5155 Guangfulin Road, Shanghai, 201600, China.
Hongya WangDepartment of Analytical Science and Development, Shanghai Henlius Biologics Co., Ltd, 5155 Guangfulin Road, Shanghai, 201600, China.
Yanjing CaoDepartment of Analytical Science and Development, Shanghai Henlius Biologics Co., Ltd, 5155 Guangfulin Road, Shanghai, 201600, China.
Lihong LuDepartment of Analytical Science and Development, Shanghai Henlius Biologics Co., Ltd, 5155 Guangfulin Road, Shanghai, 201600, China.
Wenyuan GaoDepartment of Analytical Science and Development, Shanghai Henlius Biologics Co., Ltd, 5155 Guangfulin Road, Shanghai, 201600, China.
Zhongli ZhangDepartment of Analytical Science and Development, Shanghai Henlius Biologics Co., Ltd, 5155 Guangfulin Road, Shanghai, 201600, China. zhongli_zhang@henlius.com.
Jiangsu Hengrui Medicine (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutical monoclonal antibodies are structurally and functionally complex, whereas the innovator's manufacturing processes are proprietary. With respect to the similarity assessment, a proposed biosimilar product needs to demonstrate a side-by-side comparison between the reference product (RP) and candidate product in terms of physicochemical properties and biological activities, as well as nonclinical and clinical outcomes. Here, a comprehensive analytical similarity assessment was performed for in-depth comparison of HLX04, China-sourced Avastin

Indexed as

Biosimilar PharmaceuticalsBevacizumabChinaEuropeGlycosylationBevacizumabBiosimilar PharmaceuticalsAnalytical similarityAvastin®BevacizumabBiosimilarHLX04

Identifiers

PMID37162525
OpenAlexW4376121604

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.